Financial Results for the Half Year to 30 September 2024

26 November 2024


AUDITED FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2024
MEDICARE COVERAGE CATALYSTS IN FOCUS
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
announces steady financial performance for the six months to the end of September 2024 as
it awaits the outcome of several events that have the potential to renew growth in Cxbladder
test volume and revenue.
These catalysts include Medicare Administrative Contractor, Novitas, making a favorable
policy decision on the draft ‘Genetic testing for oncology’ Local Coverage Determination
(DL39365); the American Urological Association (AUA) ongoing review of microhematuria
standards of care leading to language favorable to Cxbladder in its new guidelines; and the
Centers for Medicare & Medicaid Services (CMS) finalizing pricing recommendations for the
company’s next generation test, Cxbladder Triage Plus, that recognize its clinical and
economic value.
1H 25 FINANCIAL AND PERFORMANCE HIGHLIGHTS
1

• Operating revenue increases 1.4% on 2H 24 to $11.0 million; down 16.3% on 1H 24
reflecting Medicare uncertainty and the reduced reach of a smaller sales team. Total
revenue is down 4.4% on 2H 24 to $12.2 million
• Total laboratory throughput
2
(TLT) of Cxbladder tests down 1.1% on 2H 24 to 14,233; down
22.0% on 1H 24, commercial tests increased 3.2% on 2H 24 to 12,323 tests
• Strong performance from the Southern California Permanente Medical Group, increased
APAC volume and sustained sales force efficiencies dilute the impact of Medicare
uncertainty on test volume demand
• US test sales/FTE of 379, down 3.8% on Q1 25; US ASP
3
increases to US$618 vs US$613
in 2H 24 and $562 in 1H 24 as operating efficiencies and cash collection gains achieved in
2H 24 retained
• Net loss after tax of $14.5 million, steady on the $14.3 million net loss in 2H 24, down 4.9%
on 1H 24 net loss of $15.3 million
• Cash and cash equivalents and short-term deposits at $35.9 million; cash burn of $14.3
million is higher than $11.9 million in 2H 24, but steady after adjusting for the seasonal
impact of higher weighting of costs in 1H 25
1H 25 STRATEGIC HIGHLIGHTS
• Commercial operation retains its focus on profitable territories, non-Medicare revenue
streams and selling the clinical and economic value of Cxbladder
• Triage Plus launch plans advance; awaiting Medicare reimbursement clarity and CMS
pricing that reflects the test’s clinical and economic value

1
All comparisons are to the same period of the prior financial year unless otherwise stated.
2
Total Laboratory Throughput (TLT) includes commercial, pre-commercial and clinical studies testing.
3
ASP: US Average Sales Price (US Operating Revenue in USD / US Commercial Test Volumes)

2

• STRATA published in the Journal of Urology (May 2024) establishing clinical utility of
Cxbladder Triage; DRIVE study for the clinical validation of Triage Plus has completed
enrolment and is on track for publication in Q1 FY26; STRATA concordance study on track
for publication by 2Q FY 26
• Maintained dialogue with CMS, Novitas, C21
4
, AUA, LUGPA
5
and others regarding
‘Genetic testing for oncology’ LCD (DL39365)
• Integrated Cxbladder with Lumea Digital (US) laboratory information system and preparing
for the launch of the Pacific Edge customer portal to digitalize the customer experience for
patients and healthcare providers
Chair Chris Gallaher said: “While testing volume remains subdued as a consequence of our
efforts to preserve capital, operating revenue has increased on the second half of FY 2024,
net losses and operating cash burn have been steady on the same period. With $35.9 million
in reserves as at the end of September, the company has sufficient capital to re-establish
reliable reimbursement for our tests in the event of a negative determination from Novitas.”
Chief Executive Dr Peter Meintjes said: “I am delighted with the progress we have made
against our strategic objectives in all areas of the business. We have sustained our improved
sales force efficiency and cash collections metrics, advanced our core priorities in clinical
evidence generation, digitalization, lab operations and customer experience, while continuing
to conserve capital wherever possible.
FINANCIAL RESULTS
Operating revenue of $11.0 million was up 1.4% from $10.8 million in 2H 24, but down 16.3%
on 1H 24 reflecting the reduction in test volume in the wake of the ongoing Medicare uncertainty
and the reduced reach of the sales team following the restructuring at the start of 2H 24.
TLT of 14,233 tests was down 1.1% on the 14,393 tests in 2H 24 and down 22.0% on the
18,240 tests in 1H 24. Rising demand from the Southern California Permanente Medical
Group, rising APAC volumes and the sustained sales force efficiencies achieved as part of the
restructuring provided some mitigation to the impact of Medicare uncertainty. Commercial test
volumes rose 3.2% on 2H 24 to 12,323 tests.
The average sales price of commercial tests in the half year increased to US$618 vs US$613
in 2H 24 and $562 in 1H 24 demonstrating that we have cemented these improvements in
cash collection. As disclosed in our Q2 25 investor update, sales per average FTE in Q2 25
was down to 379 tests from 394 in the prior quarter, consistent with the lower US volumes.
Tests per unique ordering clinician (our preferred metric for measuring customer commitment
to Cxbladder) was down slightly to 6.4 in Q2 25 from 6.8 in Q1 25 reflecting the lower volume
in the quarter (ordering clinicians in Q2 25 was slightly higher at 890).

4
The Coalition for 21
st
Century Medicine, a diagnostic industry lobby organisation
5
The US Large Urology Group Practice Association

3

The net loss after tax of $14.5 million was steady on the 2H 24 net loss after tax of $14.3
million, but 4.9% lower than 1H 24 reflecting the benefits of the cash conservation initiatives.
Cash and cash equivalents and short-term deposits stood at $35.9 million at the end of
September 2024, down from $50.3 million at the end of March 2024. The cash burn of $14.3
million in 1H 25 was higher than the $11.9 million in 2H 24, with the first half of each financial
year incurring a higher cash spend related to payments that cover a 12-month period.
Excluding this higher weighting of spend in the first half of the financial year, the underlying
cash burn was steady as operating cash conservation initiatives continued to deliver.
STRATEGIC PROGRESS
Our US commercial operations remain focused on profitable territories, non-Medicare revenue
streams and selling the clinical and economic value of Cxbladder. Our front-line sales team is
operating at break even.
The moves to extend our global reach and diversify our revenue with distribution agreements
in Israel, Latin America and Southeast Asia are showing early promise, delivering still small
but steadily growing test volumes from these markets.
Supported by urological professional societies, industry partners, clinicians, and patient
advocacy groups, we believe we have made every effort to assist Novitas and the AUA to make
pragmatic decisions that recognize the clinical and economic value of our tests.
Notably we brought forward the publication of our STRATA study – the first randomized control
trial of a urine biomarker – to ensure Novitas and the AUA’s timely consideration of what is the
strongest evidence yet of Cxbladder’s clinical utility. We have also prepared plans to revert to
growth as reliable reimbursement milestones are achieved.
We have advanced our clinical evidence generation program, and we remain confident that,
over time, it will assist us to embed our existing and next generation tests in clinical guidelines,
change clinical practice among physicians and drive changes to medical policy at Medicare
and other healthcare payers.
The DRIVE Study and STRATA Concordance Study are on track for publication by mid-2025.
DRIVE has completed patient enrolment and is targeted at demonstrating the clinical validation
of Triage Plus, while the concordance study seeks to demonstrate the clinical utility of the test
by comparison of Triage Plus to Triage. In the event of a Medicare non-coverage
determination, these publications will be used as the basis of a Medicare coverage
reconsideration request.
Finally, we have continued to invest in medical affairs and the digitalization initiatives that will
further drive the adoption of our tests and improve the experience for clinicians and patients.
During 1H 25 we have completed an integration of our systems with Lumea Digital – a
pathology lab in the US with deep ties to hundreds of urology clinics in the US and made great
advancements towards deploying our customer portal, expected before the end of the calendar
year.

4

OUTLOOK
Pacific Edge is focused on establishing reliable reimbursement for Triage Plus as a precursor
to a broader commercial launch, which we anticipate in 2025.
“While headwinds remain a possibility, there are more potential catalysts to renew growth in
the US than headwinds for Pacific Edge ahead in 2025. We also benefit from a more effective,
efficient and disciplined team to drive growth with improved underlying economics. We look
forward to updating investors on our progress,” Dr Meintjes said.
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com

Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than 20 peer reviewed publications for primary detection, surveillance, adjudication of
atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous
ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.

---

1H 25 FINANCIAL RESULTS
PRESENTATION
Dr Peter Meintjes
Chief Executive Officer
Grant Gibson
Chief Financial Officer
26 November 2024

This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not
purport to be complete nor does it contain all the information which a
prospective investor may require in evaluating a possible investment in
PEL or that would be required in a product disclosure statement,
prospectus or other disclosure document for the purposes of the New
Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act 2001. PEL is subject to a disclosure obligation that
requires it to notify certain material information to NZX Limited (NZX)
and ASX Limited (ASX) for the purpose of that information being made
available to participants in the market and that information can be found
by visiting www.nzx.com/companies/PEB and
www2.asx.com.au/markets/company/PEB. This presentation should be
read in conjunction with PEL’s other periodic and continuous disclosure
announcements released to NZX and ASX.
Not an offer
This presentation is for information purposes only and is not an
invitation or offer of securities for subscription, purchase or sale in any
jurisdiction where such offer purchase or sale would not be permitted.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial
product advice or investment advice or a recommendation to acquire
PEL securities and has been prepared without taking into account the
objectives, financial situation or needs of investors. Before making an
investment decision, prospective investors should consider the
appropriateness of the information having regard to their own
objectives, financial situation and needs and consult an NZX Firm,
solicitor, accountant or other professional advisor if necessary.
Forward-looking statements
This presentation may contain forward-looking statements that reflect
PEL’s current views with respect to future events. Forward-looking
statements, by their very nature, involve inherent risks and
uncertainties. Many of those risks and uncertainties are matters which
are beyond PEL’s control and could cause actual results to differ from
those predicted. Variations could either be materially positive or
materially negative. The information is stated only as at the date of this
presentation. Except as required by law or regulation (including the NZX
Listing Rules and ASX Listing Rules), PEL undertakes no obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. To the maximum extent
permitted by law, the directors of PEL, PEL and any of its related bodies
corporate and affiliates, and their respective officers, partners,
employees, agents, associates and advisers do not make any
representation or warranty, express or implied, as to the accuracy,
reliability or completeness of such information, or the likelihood of
fulfilment of any forward-looking statement or any event or results
expressed or implied in any forward-looking statement, and disclaim all
responsibility and liability for these forward-looking statements
(including, without limitation, liability for negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated. This
presentation should be read in conjunction with, and subject to, the
explanations and views of future outlook on market conditions, earnings
and activities given recent announcements to the NZX and ASX.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the actual calculation of these figures may differ
from the figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price
performance, cannot be relied upon as an indicator of (and provides no
guidance as to) future PEL performance, including future financial
position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other
known and unknown risks, some of which are beyond the control of PEL.
PEL does not guarantee any particular return or the performance of PEL.
Disclaimer
None of PEL or PEL’s advisers or any of their respective affiliates, related
bodies corporate, directors, officers, partners, employees and agents,
have authorised, permitted or caused the issue, submission, dispatch or
provision of this presentation and, except to the extent referred to in
this presentation, none of them makes or purports to make any
statement in this presentation and there is no statement in this
presentation which is based on any statement by any of them.
To the maximum extent permitted by law, none of PEL and its advisers,
affiliates, related bodies corporate, nor their respective directors,
officers, partners, employees and agents makes any representation or
warranty, express or implied, as to the currency, accuracy, reliability or
completeness of information in this presentation; and none of them shall
have any liability (including for negligence) for:
•any errors or omissions in this presentation; or
•any failure to correct or update this presentation, or any other
written or oral communications provided in relation to this
presentation; or
•any claim, loss or damage (whether foreseeable or not) arising from
the use of any information in this presentation or otherwise arising in
connection with this presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and
conditions.
IMPORTANT NOTICE AND DISCLAIMER
2

1.HIGHLIGHTS
2.STRATEGIC DELIVERY
3.FINANCIAL PERFORMANCE
4.OUTLOOK
5.QUESTIONS
AGENDA
3

1H 25 HIGHLIGHTS: FOCUSED ON CATALYSTS FOR MEDICARE COVERAGE CERTAINTY
($14.5M)
NET LOSSAFTER
TA X
Up 1.5% on 2H 24
-4.9% on 1H 24
Global TLT of 14,233
US TLT 11,587, -4.6% on
2H 24 and -27.4% on 1H 24
Steady on 2H 24 of ($14.3M)
reflecting ‘holding pattern’ of
Medicare uncertainty
Operating revenue $11.0M
Total revenue of $12.2M
-4.4% on 2H 24
$35.9M
CASH, CASH
EQUIVALENTS
2
1H 25 cash burn of $14.3M
increases on $11.9M in 2H 24
but steady adjusting for
seasonal impact of costs
3.2%
COMMERCIAL
TEST VOLUMES
on 2H 24
-20.0% on 1H 24
1.1%
GLOBAL TESTS
( T LT
1
) on 2H 24
-22.0% on 1H 24
1.4%
OPERATING
REVENUE on
2H 24
-16.3% on 1H 24
Commercial Tests of 12,323
US Commercial Tests 9,911,
-0.5% on 2H 24 and –26.9%
on 1H 24
1.Total Laboratory Throughput (TLT) including commercial, pre-commercial and clinical studies testing
2.Cash, short-term deposits and term deposits
3.ASP: US Operating Revenue in USD / US Commercial Test Volumes
4
•Awaiting outcome on catalysts: Medicare coverage certainty, AUA hematuria guideline review and Triage Plus pricing
•Operating revenue, net losses, and operating cash burn steady as operating efficiencies and cash collection gains retained. US test sales/FTE of
379 in Q2 25, - 3.8% on Q1 25; US ASP
3
increases to US$618 in 1H 25 vs US$613 in 2H 24
•Commercial operations focused on profitable territories, non-Medicare revenue streams and selling the clinical and economic value of
Cxbladder; direct sales team efficiencies maintained - operating at break even
•Business focused on the clinical development for Triage Plus and Monitor Plus

VALUE CREATION THROUGH THREE PILLARS
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS
A VALUES DRIVEN, DIVERSE, RESULTS-FOCUSED CULTURE
SCALABLE PROCESSES, TRAINING & QUALITY SYSTEMS,CONTINUOUS IMPROVEMENT
DIGITALIZED ARCHITECTURE, AUTOMATED OPERATIONS, REAL-TIME ANALYSIS
5

17%
60%
23%
33%
48%
19%
TEST VOLUMES STEADY AGAINST 2H 24 AMID MEDICARE UNCERTAINTY
1H 24
TEST VOLUMES BY TYPE (TLT*)
GLOBAL COMMERCIAL TEST VOLUMES (TLT*)
GLOBAL TOTAL TEST VOLUMES (TLT*)
1H 25 TOTAL LAB THROUGHPUT (TLT*)
•Global TLT of 14,233 for 1H 25 steady (-1.1%) on 2H 24 and down
22% on 1H 24 amid ongoing Medicare coverage uncertainty and
reduced reach of the sales force
•Global Commercial test volumes of 12,323 for 1H 25 up 3.2% on 2H
24 and down 20% on 1H 24
•Triage growing in share of volume validating risk stratification value
proposition and investment in Triage Plus
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
1H 25
6
1H
2H
1H
2H
11,136
14,920
18,240
14,233
11,950
16,645
14,393
23,086
31,565
32,633
-
5,000
10,000
15,000
20,000
25,000
30,000
35,000
FY 22FY 23FY 24FY 25
TESTS
9,192
12,422
15,401
12,323
10,004
14,269
11,946
19,196
26,691
27,347
-
5,000
10,000
15,000
20,000
25,000
30,000
FY 22FY 23FY 24FY 25
TESTS

FOUNDATIONS FOR GROWTH - US TEST VOLUMES STEADY
•US TLT in Q2 25 relatively stable on the prior quarter (Q1 25)
•Strong performance from the Southern California Permanente
Medical Group and sustained sales force efficiency gains deliver
some mitigation to the impact of Medicare uncertainty
•Throughput has reduced by 34.1% from a peak of 8,627
test/quarter in Q1 24 to 5,682 in Q2 25 as the sales team
reduced in 2H 24 and no backfill appointments in sales force
•Sales territories are larger and more challenging for sales reps,
but focus has been on larger, more reliable accounts
•Messaging has focused on communicating the clinical value of
Cxbladder for risk stratification to reduce cystoscopies and the
associated economics of adopting on all appropriate patients
US TOTAL TEST VOLUME*
*
Total Laboratory Throughput in the US including commercial, pre-commercial and clinical studies testing
KAISER PERMANENTE GAINS PARTIALLY OFFSET MEDICARE UNCERTAINTY
6,073
6,699
6,629
7,816
8,627
7,335
6,041
6,099
5,905
5,682
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25
TEST VOLUMES
7

FOUNDATIONS FOR GROWTH – PERFORMANCE IMPROVEMENTS SUSTAINED
US SALES FORCE EFFICIENCY
US CLINICAL COMMITMENT
•Sales FTE down to an average of 15.0 in Q2 25 from 32.7 in
Q4 23 as we focused on cash conservation:
•Sales FTEs were reduced by restructure in late Q2 24
•Sales FTEs leaving the business are backfilled only
when sales force breakeven can be maintained
•Sales force efficiency (total tests/average FTE) sustained up
59% from 239 in Q4 23 to 379 in Q2 25:
•More effective core sales team
•Focus on the most profitable territories/accounts
•Tests/US ordering clinician stable, but ordering clinicians fall
against 1H 24:
•Change in clinical mix in favor of clinicians that
understand the clinical utility of Cxbladder
•Reduced reach of the direct sales team
•Direct sales team have achieved operational break even
SALES TEAM FOCUSED ON KEY PERFORMANCE INDICATORS
27.3
29.7
33.0
32.7
30.0
27.7
20.7
16.0
15.0 15.0
222
226
201
239
288
265
292
381394379
0
50
100
150
200
250
300
350
400
0
10
20
30
40
50
60
70
80
Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25
VOLUME /SALES FTE
AVERAGE SALES FTE
US TEST VOLUME/SALES FTE (RHS)
895
978
1,082
1,150
1,232
1,147
1,016
915
869
890
6.8
6.8
6.1
6.8
7.0
6.4
5.9
6.7
6.8
6.4
0
1
2
3
4
5
6
7
8
-
200
400
600
800
1,000
1,200
1,400
1,600
Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25
TEST/ORDERING CLINICIAN
US ORDERING CLINICIANS
TESTS/ORDERING CLINICIAN (RHS)
8

FOUNDATIONS FOR GROWTH - US CASH COLLECTIONS IMPROVE
•Average Sales Price (ASP*) per test increased to US$618 from
US$613 in 2H 24 and US$519 in 2H 23 lifted by:
•Enhanced Patient Responsibility - patients with non-
contracted private insurance (i.e. non-Kaiser) pay a fixed
dollar amount “maximum out of pocket”
•Increased utilization of appropriate patient types from
Kaiser Permanente after EMR integration
•Medicare reimbursement of Triage since Jan 2023
•Improved medical necessity documentation to improve
billing and appeals processes for Medicare Advantage
•Improved cash collections are typically permanent
improvements that we expect to maintain as we scale
*
ASP: US Operating Revenue in USD / US Commercial Test Volumes
US COMMERCIAL TEST VOLUMES AND ASP* (US$)
REIMBURSEMENT & CASH COLLECTIONS – A CORE COMPETENCY
7,476
8,276
10,622
12,450
13,550
9,956
9,911
$472
$470
$493
$519
$562
$613
$618
$-
$100
$200
$300
$400
$500
$600
$700
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
1H 222H 221H 232H 231H 242H 241H 25
US$ AVERAGE TEST SALE PRICE
TEST VOLUME
US ASP (RHS)
9

DRIVING GROWTH IN ASIA PACIFIC AND CONSOLIDATING NEW ZEALAND
*
Total Laboratory Throughput in Asia and Pacific including commercial, pre-commercial and clinical studies testing
•Quarterly total test volumes benefit from:
•Fewer evaluations and non-billable tests
•Shift in emphasis to commercial tests
•New Zealand is a mature market with Cxbladder utilized in 15 of the
20 Te Whatu Ora health regions covering >75% of the population
AUSTRALIA & ASIA PACIFIC
•Australia and Southeast Asia are still in business development
•Initial commercial testing volume direct or via distributors in
Singapore, Malaysia, Brunei, Thailand and the Philippines
APAC TOTAL TEST VOLUMES*
Sept ’24 - ceremonial signing of partnership agreement with
Malaysia’s Premier Integrated Labs in Kuala Lumpur
983
1,165
1,139
1,061
1,079
1,199
1,142
1,111
1,283
1,363
-
200
400
600
800
1,000
1,200
1,400
1,600
Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25
TEST VOLUMES
10

1. RDM: Residual Disease Monitoring,
2. TRM: Therapeutic Response Monitoring
3. Lotan et al (2022) ‘Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification’; NPV: Negative
Predictive Value; PPV: Positive Predictive Value; ROR: Rule out Rate
SIMPLIFYING THE CXBLADDER VALUE PROPOSITION – TRIAGE PLUS
TRIAGE PLUS NAMING ALIGNS WITH CLINICAL POSITIONING AND STRATA
1
EVIDENCE
TRIAGE PLUS – THE ADDITION OF DNA BIOMARKERS LIFTS PERFORMANCE
3
•Triage Plus combines the value propositions of the existing Triage and the Detect tests in a
single test for the evaluation of hematuria, the largest market opportunity
•A negative test helps clinicians to rule out the presence of cancer due to the high Negative
Predictive Value and Sensitivity
•A positive test can help clinicians to resolve diagnostic dilemmas and prioritize patients for
a more intensive workup due to the high Specificity and Positive Predictive Value
Performance
3
SensSpecNPVPPVROR
Triage Plus97%90%99.7%44%83%
Triage89%63%99%16%59%
Detect74%82%97%25%78%
11

PREPARING FOR THE

COMMERCIALIZATION OF TRIAGE PLUS
EXPANDING AND EXTENDING OUR LEADERSHIP POSITION IN HEMATURIA EVALUATION
ESSENTIAL PRE-CONDITIONS TO LAUNCHING TRIAGE PLUS
•Pricing that reflects the clinical value and economic benefit of the test
•Reliable Medicare reimbursement via (existing) coverage of our tests or through
new arrangements following Novitas policy decision on the draft ‘Genetic testing
for oncology’ LCD (DL 39365)

COMMERCIAL PREPARATORY WORK
•Driving for coverage and reimbursement of Triage Plus
•Adding capabilities and capacity to PEDUSA laboratory
•Simplifying laboratory workflow for improved efficiency
•Optimizing sales team structure for expanded product adoption
•Preparing sales and marketing training materials
•Enhancing medical education with a speaker bureau, podium presentations, and
evidence development
12

TRIAGE PLUS PRICING STANDS TO BOLSTER PACIFIC EDGE’S ECONOMICS
PRICING OF TRIAGE PLUS IS THE NEXT STEP IN THE COMMERCIALISATION PROGRAM
Dates future to this presentation are anticipated timeframes for Triage Plus pricing - dates may change
1
In November 2024 Pacific Edge changed the name of Detect
+
to Triage Plus.

We may continue to use the former name in certain formal documents as necessary, and will seek to
amend the descriptor for CPT Code 0420U CPT to Triage Plus through the quarterly administrative process with CMS
•Determining a CMS price for Triage Plus (0420U) is
the next step in establishing reimbursement
•Advisory Panel and CMS have recommended Gapfill
for Triage Plus
•Pacific Edge and C21 have provided counter-
arguments during public comment period
supporting a Crosswalk recommendation
•Gapfill is the more likely outcome, requires all MACs
to recommend a price and takes 12 months to
finalize
•Pacific Edge will seek a ‘provisional local price’ for
Triage Plus from Novitas during the Gapfill process
to ensure Gapfill imposes no delays on the
commercial launch of Triage Plus
13

Cystoscopy
undertaken
Pacific Edge’s budget impact modelling shows Cxbladder offers better care, avoids unnecessary procedures and
improves workflow when used to intensify or de-intensify hematuria evaluation or in the surveillance for the recurrence
of bladder cancer. For healthcare payers Cxbladder offers substantial total cost savings per patient
1,2
1. Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)
2. Tyson et al (2024). Modelling the impact of incorporating Cxbladder Monitor in the surveillance of patients after non-muscle invasive bladder cancer in the US. abstract presented
to the WSAUA in Kauai, Hawaii
3. Pacific Edge’s model assumes a 5% incidence of bladder cancer in patients presenting with hematuria and referred to a specialist for a urological work up.
SELLING CXBLADDER’S CLINICAL, ECONOMIC AND PATIENT VALUE
CXBLADDER DETECT VS AUA GUIDELINES
CXBLADDER MONITOR VS AUA GUIDELINES
HEMATURIA EVALUATION
1
•Cxbladder Detect rules out 78 of the
95
3
patients without cancer and
requires only 22 cystoscopies to find
the five patients with cancer
•This results in savings of >US$500 per
patient presenting with hematuria
CANCER RECURRENCE SURVEILLANCE
2

•Cxbladder Monitor alternated with
cystoscopy for surveillance of
bladder cancer after nine months of
treatment
•This results in 12.4% reduction in
cystoscopies over a five-year
surveillance period
•Savings estimated at as much as
US$680 per patient over the five-
years
Cystoscopy
undertaken and
cancer found
Cystoscopy
avoided
Surveillance
cystoscopy
undertaken
Surveillance
cystoscopy
avoided
14

STRENGTHENING OUR CUSTOMER EXPERIENCE
DRIVING ‘STICKINESS’ AND LONG-TERM MARKET SHARE
THE BEST AND MOST CUSTOMER-FRIENDLY TEST
•Give customers options to connect with Pacific Edge to fit
their needs with easy-to-use digital workflows
•Electronic Medical Record (EMR) integrations (Kaiser)
•Pacific Edge Customer Portal
•Pathology Lab LIS integrations (Lumea, Awanui)
•Improvement of end-to-end experience for patients and
providers
•Example of “one-to-many” integrations to clinics
KAISER EMR SUPPORTING ADOPTION
•EMR integration went live in Nov 2023 across Kaiser’s Southern California
Permanente Medical Group streamlining sample collection, test ordering
and test resulting for Triage and Monitor
•All 15 Kaiser SoCal sites are now ordering and volumes increasing steadily
•Primarily adopted for Triage, Monitor volume is beginning to rise as
clinicians become increasingly familiar with Cxbladder
•Kaiser SoCal represents ~37% of the >12.6m members covered by Kaiser
Permanente, longer term we are targeting other regions
15
View of the Lumea BxLink interface

AUA HEMATURIA GUIDELINES – A COMPREHENSIVE REVIEW
AN APPROACH THAT SUPPORTS OUR DRIVE FOR GUIDELINE INCLUSION
•The AUA has commenced a review of the microhematuria guideline and has asked for
professional comment on its initial draft; no timeframe provided
•The clinical utility of Cxbladder Triage demonstrated by the STRATA
1
study is expected
to be considered as part of the deliberations
•A positive AUA Journal of Urology editorial in July 2024 suggests favorable direction of
travel
•Clear/positive inclusion language would be used as the basis for a Medicare coverage
re -consideration request (in the event of a non-coverage determination)
“... these tests have the potential to improve the
management of our patients with suspected
[urothelial cancer] who would otherwise require an
invasive procedure for diagnosis.”
– Journal of Urology editorial Sept 2024
www.auanet.org
•Globally the most influential and largest
urologicalassociation
•Relevant standards of care: Hematuria,
microhematuria management and non-
muscle invasive bladder cancer (NMIBC)
•Review period: with new evidence, last
updated in 2020
1. Lotan et al. (2024) . A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The
Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.
16

‘GENETIC TESTING FOR ONCOLOGY’ LCD PROCESS EXTENDED
CMS
1
APPROVED THE EXTENSION TO GIVE NOVITAS
1
TIME TO RESPOND TO ALL COMMENTS
EXTENSION INCREASES CONFIDENCE TOWARDS MEDICARE COVERAGE CERTAINTY
•Cxbladder continues to receive reimbursement from Medicare and Medicare
Advantage payers in line with historical reimbursement rates
•Novitas confirmed by email that they are reviewing all Pacific Edge submissions
alongside the comments received during the comment period
•Pacific Edge continues to engage with Novitas and CMS with the support of
professional societies, industry partners, clinicians and patient advocacy groups
•Pacific Edge and C21
3
have taken separate but supporting actions to have DL39365
retired, including engagement with the Office of the General Counsel
3

•We remain prepared to explore legal action in the event of a non-coverage
determination
27 July 2023
Novitas
1
republishes draft LCD
9 September 2023
Review and commentperiod closes
Nov 2023 – Jan 2024
Meetings between Pacific Edge and CMS
26 - 29 July 2024
Pacific Edge learns CMS has granted
Novitas an extension beyond statutory
365-day finalization timeline
DECISION (STILL) PENDING
July 2024 - Present
Pacific Edge and industry partners engage
with Novitas and CMS
CMS says extension is “not indefinite”
Finalization or retirement remain possible
MEDICARE IS PACIFIC EDGE’S LARGEST PAYER
•Medicare and Medicare Advantage is the largest global opportunity in
bladder cancer diagnostics from a single coverage decision
•In 1H 25 Medicare and Medicare Advantage delivered ~5,300commercial
tests (~54% of US commercial tests) and ~$6.5m NZD in total operating
revenue (~59% of total operating revenue)
1. Novitas is the Medicare Administrative Contractor for Pacific Edge’s US laboratory. It is empowered by the Centers for Medicare and Medicaid Services (CMS) to make the
coverage determination, but it is accountable to CMS for the decision.
2. Lotan et al. (2024) . A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk
for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.
3. C21 is a diagnostic industry lobby group the Coalition for 21st Century Medicine. The Office of the General Counsel (OGC) is the legal team for the US Department of Health and
Human Services (HHS)
17

CLINICAL EVIDENCE CATALYSTS FOR COVERAGE CERTAINTY
Pacific Edge will also lodge a reconsideration request if Cxbladder is included in the American
Urological Association (AUA) or National Comprehensive Cancer Network (NCCN) guidelines
MEDICARE RECONSIDERATION AND GUIDELINE INCLUSION REQUESTS
(Novitas
1
typically handles reconsideration requests on existing LCDs within three months of submission)
CatalystTest and evidence standard
(2)
Expected date of reconsideration request
(3)
1. STRATA data published-CU of TriageNovitas notified of the publication in April
2. Automated RNA and DNA extraction-AV of Triage, Detect and MonitorQ3 2024 (Published September, Novitas notified)
3. Triage Plus Analytical Validation-AV of Triage Plus Q2 2025
4. DRIVE data published-CV of Triage PlusQ2 2025
5. STRATA concordance -CU of Triage Plus (concordance)Q3 2025
6. Kaiser Permanente RWE
4
published-CU of Triage (RWE) Q3 2025
5
7. AUSSIE data published-CVof Triage PlusQ4 2025
8. microDRIVE published-CV of Triage PlusQ1 2026
9. Monitor Plus Analytical Validation-AV of Monitor PlusQ2 2026
10. Pooled CV data published
6
-CV of Triage PlusQ2 2026
11. LOBSTER published-CV of Monitor/Monitor PlusQ1 2027
12. CREDIBLE data published-CU of Triage PlusQ3 2027
1
Novitas is the Medicare Administrative Contractor (MAC) charged with making the Medicare local coverage determination for Pacific Edge’s US laboratory
2
AV, CV CU, respectively Analytical Validity, Clinical Validity, Clinical Utility
3
All dates are calendar year rather than financial year and our best current estimates
4
RWE is Real World Evidence
5
Timeline determined by Kaiser Permanente
6
The pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
18

1,563
Low-risk patients took a
Cxbladder Triage test
Patients:
- Had no history of
gross hematuria; or
- Refused cystoscopy
1,200 (77%)
NEGATIVE RESULT
Avoided a cystoscopy
363 (23%)
POSITIVE RESULT
Identified as ‘high-risk’
of cancer
310
Underwent a
cystoscopy
19
Diagnosed with cancer
(6.1% of those
examined)
INDEPENDENT REAL-WORLD EVIDENCE OF CXBLADDER’S CLINICAL UTLITY
CLINICAL UTILITY EVIDENCE OF CXBLADDER TRIAGE THAT SUPPORTS MEDICARE COVERAGE
1.
Real World Clinical Utility of a Urinary Biomarker (Cxbladder Triage) for Hematuria Referrals in an Integrated Managed Care Health System. Abstract accepted for presentation to
the Western Section of the American Urological Association annual conference.
KAISER PERMANENTE ABSTRACT SHOWS CLINICAL VALUE IN REAL WORLD SETTING
•Kaiser Permanente presented an abstract to the Western Section AUA conference
regarding their ongoing experience with Cxbladder Triage
•The abstract focuses on 1,563 low-risk patients in the Kaiser Southern California
health system with no history of gross hematuria or who refused cystoscopy
•1,200 patients avoided invasive cystoscopy, improving patient satisfaction,
urology access and lowering the overall cost of care
•A peer-reviewed publication is expected on the complete data set, targeting the
AUA conference in 2025
•Pacific Edge will use this future publication for a Medicare reconsideration request
(in the event of a non-coverage determination)
“Incorporating a highly reliable urine biomarker into clinical workflows for
hematuria reduced the burden of cystoscopy substantially, improving patient
satisfaction, urology access, and lowering overall cost of care,”
- Loo et al (2024)
1
19

STRATEGIC RESPONSES TO THE IMPENDING MEDICARE DETERMINATION
OUR RESPONSE TO AN AFFIRMATION OF COVERAGE
•Strategic review to accelerate the US adoption of
Cxbladder among patients, clinicians, and healthcare
payers​​
OUR RESPONSE TO A LOSS OF COVERAGE
•Explore legal options supported by customers, industry
partners and other impacted companies
•Further review the structure of our operations and our
strategy to reduce cash burn in line with our plan to
regain Medicare coverage within our existing cash
reserves
•Continue to explore other strategic alternatives for Pacific
Edge that could support the company through to
regaining Medicare coverage and advancing the
commercialization of Cxbladder globally
LONG TERM VALUE CREATION STRATEGIES WILL CONTINUE
•Continue to advance our clinical evidence generation program for
inclusion in AUA and NCCN
1
Guidelines for increased coverage
certainty​
•Continue to invest in medical affairs and the digitalization initiatives
that will enable clinicians who continue to order Cxbladder to
follow clinical pathways on all appropriate patient types
Distribution of Current
U.S. Customers
Pacific Edge Diagnostics
USA, Hershey,
Pennsylvania
1. AUA: American Urological Association; NCCN: National Comprehensive Cancer Network
20

RESEARCH & INNOVATION – FOCUSED ON DNA ENHANCED PRODUCTS
READYING FOR THE LAUNCH OF TRIAGE PLUS AND MONITOR PLUS
•Ensure R&D, Digital and Lab Operations focus on the commercial
scaling of Triage Plus and Monitor Plus
•Simplifying Cxbladder:
•Aim to reduce technician time, lower cost of goods, lower
turnaround time, increase throughput and increase automation
•Aim to be IVD-ready with “kittable” Cxbladder tests for
decentralized deployment for international market expansion
•Analytical Validation (AV) of automated end-to-end lab
operations for RNA and DNA workflows.
•AV data for the automated Cxbladder (Triage, Detect and
Monitor), i.e. RNA is now published
1
•Establish in-vitro diagnostic (IVD) regulatory framework for R&D of our
next generation tests
•Continued engagement with industry and academic research and
development collaborations to address unmet clinical needs in bladder
cancer diagnosis and management
1. Harvey et al (2024). Analytical Validation of Cxbladder®Detect, Triage, and Monitor: Assays for Detection and Management of Urothelial Carcinoma.Diagnostics. 2024;
14(18):2061. https://doi.org/10.3390/diagnostics14182061
Chief Scientific Officer Parry Guilford (center) and Chief Technology
Officer Justin Harvey (right)
21

FINANCIAL PERFORMANCE
22

8%
92%
5%
95%
$3,326
$5,378
$8,707
$13,095
$10,959
$4,375
$6,067
$10,909
$10,812
$7,701
$11,445
$19,616
$23,907
$0
$5,000
$10,000
$15,000
$20,000
$25,000
FY 21FY 22FY 23FY 24FY25
$(000)
1H2H
US COMMERCIAL TEST VOLUME GROWTH DRIVING REVENUE
LOOKING TO US CATALYSTS TO DRIVE A RECOVERY IN REVENUE GROWTH
PACIFIC EDGE OPERATING REVENUE
1H 24
1H 25
REGIONAL REVENUE CONTRIBUTION
APAC
AMERICAS
-16.3%
vs 1H 24
23

CAPITAL FOCUSED ON EVIDENCE GENERATION FOR RELIABLE REIMBURSEMENT
•Cash, cash equivalents and short-term
deposits of $35.9M vs. $50.3M as at 31
March 2024
•Cash burn of $14.3M vs. $12.0M in 2H 24 –
Seasonal impact of higher weighting of costs
in 1H 25 compared to the expectation for 2H
25
•The capital preservation initiatives continue
to deliver
•Investment now primarily focused on long-
term strategic initiatives
•Cash runway sufficient to re-establish reliable
reimbursement
1
A STRONG BALANCE SHEET
$105,412
$93,455
$77,791
$62,174
$50,261
$35,931
$11,957
$15,664 $15,617
$11,913
$14,330
$-
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
$16,000
$-
$20,000
$40,000
$60,000
$80,000
$100,000
$120,000
31-Mar-2230-Sep-2231-Mar-2330-Sep-2331-Mar-2430-Sep-24
CASH BURN (NZ$000)
CASH AND CASH EQUIVALENTS (NZ$000)
HALF YEAR CASH AND CASH EQUIVALENT BURN (RHS)
24
1. Refers to scenarios that model a loss of Medicare reimbursement

REVENUE STEADY; INCREASE IN ASP OFFSETS THE IMPACT OF LOWER VOLUME
•Operating revenue increases 1.4% on 2H 24 despite
lower volumes following lift in ASP
1
to US$618 vs.
US$613 in 2H 24
•Total revenue includes FX loss of $0.4M, while 1H 24
recorded a $0.7m FX gain and 2H 24 recorded a FX
loss of $0.1m
•Total operating expenses steady on 2H 24 as
restructuring gains of late Q2 24 retained
•Balance sheet remains strong and expected to be
sufficient to regain coverage in the event of a non-
coverage decision
FINANCIAL PERIOD
1H 25
vs.
1H 25
vs.
1H 252H 241H 24FY241H 242H 24
$000$000$000
△

%
△

%
Operating revenue
$10,959$10,812$13,095$23,907-16.3%1.4%
Total revenue
$12,155$12,713$16,580$29,293-26.7%-4.4%
Operating expenses
$26,658$26,996$31,832$58,828-16.3%-1.3%
Net Loss After Tax
-$14,503-$14,283-$15,252-$29,535-4.9%1.5%
Cash receipts from
customers
$11,125$10,561$13,576$24,137-18.1%5.3%
Net operating cash burn
$12,474$10,758$14,992$25,750-16.8%16.0%
Net cash, cash equivalents
and short- term deposits
$35,931$50,261$62,174$50,261-42.2%-28.5%
1. ASP: US Operating Revenue in USD / US Commercial Test Volumes
25

OPERATING EXPENSES STEADY ON PRIOR HALF
INVESTMENT NOW FOCUSSED ON LONG-TERM STRATEGIC INITIATIVES
•Operating expenses are steady on 2H 24
•The 16.3% reduction vs. 1H 24 isdue to
theshift in focus to preserve cashwhile
enhancing clinical evidence
oLaboratory operations largely driven by
volume and preparing for the commercial
launch of Triage Plus.
oRise in researchexpenses reflects
continued investment inclinical evidence
to create catalysts for coverage.
oSales and marketing expense reduction
vs 2H 24 reflects thesharp focus on the
most the profitable territories/accounts
oGeneral and administration expenses are
higher as a result of receiving a higher
proportion of overheads.
FINANCIAL PERIOD
1H 252H 241H 24FY24
1H 25
vs.
1H 25
vs.
1H 242H 24
$000$000$000$000
△

%
△

%
Laboratory operations $5,958$5,610$6,141$11,751-3.0%6.2%
Research$7,230$6,602$5,487$12,08931.8%9.5%
Sales and marketing $8,245$11,251$14,339$25,590-42.5%-26.7%
General and administration$5,225$3,533$5,865$9,398-10.9%47.9%
Total operating expenses$26,658$26,996$31,832$58,828-16.3%-1.3%
26

SUMMARY AND OUTLOOK
27

READY FOR ALL OUTCOMES
•We continue to manage our cash prudently while we seek to maintain reliable reimbursement for existing products and establish
reimbursement for future products
•We will continue to:
•Engage directly and through industry partners with CMS/Novitas to preserve reimbursement of our existing portfolio of tests
•Focus on the clinical development of Triage Plus and Monitor Plus for guidelines inclusion and increased coverage certainty
•Focus our commercial operations on profitable territories, non-Medicare revenue streams and cash collections
•Emphasize the clinical and economic value of Cxbladder in our sales messaging
HEADWINDS:
•Possible non-coverage determination from Novitas on a new proposed LCD after following appropriate ‘notice and comment’
procedure
•Possible negative physician or patient response to enhanced patient responsibility on commercial insurance
C ATA LYST S :
•Possible inclusion of Cxbladder Triage in AUA microhematuria guidelines amendment
•Possible retirement of Novitas LCD (DL39365)
•Possible re-coverage determination from Novitas on new proposed LCD after following appropriate procedure
•Crosswalk or ‘provisional pricing’ for Cxbladder Triage Plus at greater margin than the current generation of products
28

APPENDIX

PACIFIC EDGE’S GLOBAL REACH
30

PACIFIC EDGE’S EVIDENCE PROGRAM SEEKS TO CHANGE CLINICAL PRACTICE
Clinical Evidence
AV, C V, C U
HEALTHCARE PAYERS
(Medicare, Kaiser
Permanente, Veterans
Administration, private
payers, etc).
- Change Medical Policy
(practice)
- Change Reimbursement
Policy
PROFESSIONAL SOCIETIES
(AUA, EAU, NCCN)
- Change Standard of Care
Guidelines
Guidelines change:
- Healthcare Payer Medical
and Reimbursement
Policies
Guidelines change:
- Clinical Practice
UROLOGISTS - Change Clinical Practice
STRUCTURED CLINICAL EVIDENCE DEVELOPMENT
•Pacific Edge’s clinical study program is focused on developing clinical evidence for Cxbladder tests in a structured framework
•Analytical Validity (AV): Evidence that a test is repeatable in the lab for a given indication and population
•Clinical Validity (CV): Evidence a test works in the same way on an independent eligible population for a given indication
•Clinical Utility (CU): Evidence that a test changes clinical practice in the hands of a physician, typically in prospectively recruited RCTs
•Real World Evidence (RWE): CU verification of the real-world use of the test in clinical practice, usually through regular use of the test by physicians
•Clinical Utility evidence obtained through randomized control trials is required to change standard of care guidelines (in addition to AV and CV evidence)
AUDIENCE
EVIDENCE USE
31

HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP
Calendar
year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
S T R ATA
DRIVE
AUSSIE
microDRIVE
Pooled CV
CREDIBLE
*
*
*
*
*
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
DBL
DBL
32

SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP
Calendar
year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
“The 1800”
LOBSTER
USCU
Surv
*
33

SUMMARY OF CLINICAL EVIDENCE
StudyPop. TypeSensitivity (Sn)NPVSpecificity (Sp)
Comment
Triage Plus
Proof of
concept
Lotan et al., 2022MH + GH*97%99.7%90%Pooled data from US and Singapore cohorts (n=804). Called Detect+ in publication.
CV
DRIVE (unpublished) (1)MH + GH*Study in progress
AUSSIE (unpublished) (4)MH + GH*Study in progress
microDRIVE (unpublished) (5) MH*Study in progress
CUCREDIBLE (not started)(6)MHProtocol in final development stages, site selection starting by the end of year.
Triage
AVKavalieris et al., 2015MH + GH*95.10%98.50%45%Sn, Sp, NPV values when test-negative rate is 40%
CV
Davidson et al., 2019MH + GH*95.5% (1)98.6% (1)34.3%GH only: Sn (95.1%), NPV (98%), Sp (32.8%); MH only: Sn (100%), NPV (100%), Sp (42.6%)
Konety et al., 2019(2)100%
Cxbladder (3) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 4)
Lotan et al., 2022MH + GH*89%99%63%Pooled data from US and Singapore cohorts (n=804)
CU
Davidson et al., 2020MH + GH*89.4% (5)98.9% (5)59% (5)
39% of patients testing negative for Cxb Triage & imaging did not get cystoscopy & were
managed at primary care (6)
Lotan et al., 2024 (7)MH + GH*90%99%56%
Showed clinicians using Triage undertook 59% fewer cystoscopies on low-risk patients
presenting with hematuria.
Detect
AVO'Sullivan et al., 2012GH*81.8%97%85.1%Cxb Detect detected 97% of HG tumors & 100% of Stage 1 or greater tumors
CV
Lotan et al., 2022MH + GH*74%97%82%Pooled data from US and Singapore cohorts (n=804)
DRIVE (unpublished) (1)MH + GH*Study in progress
Health
Economics
Tyson et al., 2023 MH
Published economic model shows significant savings for healthcare payers (median savings of
$559 in direct costs per patient)
Monitor
AVKavalieris et al., 2017(1)88% (2)97% (2)N/A(3)
CVKonety et al., 2019(4)100%
Cxbladder (5) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 6)
CUKoya et al., 2020(7)
Integration of Cxb Monitor into the surveillance schedule reduced annual cystoscopies (39%)
(8,9)
CULi et al., 2023(7)
Cxbladder Monitor safely postpones a patient’s next scheduled cystoscopy, the current ‘gold
standard’ for bladder cancer surveillance
* Referred patients. Definitions - MH: Microhematuria, GH: Gross Hematuria. For Sensitivity, NPV and Specificity please see page 41 of this presentation

FOOTNOTES FOR CLINICAL EVIDENCE SUMMARY
Footnotes
Triage Plus
1Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Triage Plus).
2Observational study to validate performance characteristics of Cxb Triage Plus in patients with UC of the upper tract.
3Patients with suspected upper tract UC (UTUC) or surveillance patients with a history of UTUC.
4Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Triage Plus).
5Observational study to validate performance characteristics of Cxb Triage Plus in microhematuria (MH) patients.
6Clinical utility study comparing the reduction of cystoscopy use when implementing the new clinical pathway to SOC in a defined MH population.
Triage
1
Cxb Triage performance; Cxb Triage & imaging combined performance had a Sn of 97.7% & NPV of 99.8%.
2
Patients included hematuria evaluation (n=436) or surveillance previously diagnosed with UC (n=416) with both Cxbladder & urine cytology results.
3
Cxbladder includes Cxbladder Triage & Cxbladder Monitor.
4
This included n=70 for patients with hematuria & n=83 for patients with previously diagnosed UC and overall test negative rate of 30.7%.
5Cxb Triage performance; Cxb Triage & imaging combined performance had a Sn of 98.1%, NPV of 99.9% & Sp of 98.4%.
6Cxb Triage negative rate was 53%; Follow-up period of 21-months showed no missed cancers, demonstrating safety.
7
Cxb Triage demonstrated to have clinical utility in safely risk stratifying low risk microhematuria patients and not undertake cystoscopy.
Detect
1
Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Detect
+
).
Monitor
1
Surveillance patients previously diagnosed with primary or recurrent UC.
2
Cxb Monitor performance characteristics on surveillance patients diagnosed with primary UC; Cxb Monitor had a Sn of 93% and NPV of 94% on patients with recurrent UC.
3
Using Kavalieris et al., (2017) data set, Lotan et al., (2017) compared relative performance of Cxb Monitor against NMP22 ELISA, NMP22 BladderChek and urine cytology.
4Patients included hematuria evaluation (n=436) or previously diagnosed UC (n=416) with both Cxbladder & urine cytology results.
5Cxbladder includes Cxbladder Triage & Cxbladder Monitor.
6
This included n=70 for patients with hematuria & n=83 for patients with previously diagnosed UC; test negative rate of 30.7%.
7
All patients were being evaluated for recurrence of UC (n=309 providing 443 samples).
8
Cxb Monitor identified all seven confirmed recurrence events idnetified on the first cystoscopy.
9
Patients returning negative Cxb Monitor results (n=235) had no pathology-confirmed recurrence at 1st cystoscopy
35

REFERENCES SUMMARY OF CLINICAL EVIDENCE
References
Triage Plus
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification
1
. The Journal of Urology, 10-1097.
Triage
Davidson et al., (2019). Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy.NZ Med J,132(1497), 55-64.
Davidson et al., (2020). Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy.The New Zealand Medical Journal (Online),133(1527), 71-82.
Kavalieris et al., (2015). A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage outpatients presenting with hematuria who
have a low probability of urothelial carcinoma.BMC urology,15(1), 1-12.
Konety et al., (2019). Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
Lotan et al. (2024) . A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic
Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024.
Detect
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
O'Sullivan et al., (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.The Journal of urology,188(3), 741-747.
Monitor
Kavalieris et al., (2017). Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study.The Journal of Urology,197(6), 1419-1426.
Konety et al., (2019). Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Koya et al., (2020). An evaluation of the real-world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.BMC urology,20(1), 1-9.
Lotan et al., (2017). Clinical comparison of non-invasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 35 (8), 531-539.
Li et al., (2023). Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 41 (7), 326.e1 – 326.38.
36
1.Triage Plus was called Detect+ in this publication

KEY CLINICAL ADVISORS AND CONSULTANTS
Associate Professor Katie Murray, DOMS, FACS
Institution: NYU Langone
Relationship: Consultant, CAB member,
Brief Bio: Published >80 articles. Deputy Editor for J Urol.
Leadership roles for SUO Young Urologic Oncology Clinical Trials
Professor Jonathan Wright, MD, MS, FACS
Institution: Fred Hutchinson Cancer Center at UW
Relationship: Consultant, CAB member, CT PI
Brief Bio: Member of ACS, SUO, AUA
Professor Wade Sexton, MD
Institution: University of South Florida & Moffitt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. NCCN Bladder Cancer
guidelines, AUA Annual Board Review Course
Professor Jay Raman, MD
Institution: Penn State and Hershey Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >350 articles. Chair of AUA Office of Education
and Past-President of the Mid-Atlantic AUA section. Urology
Advisory Council for ACS, hematuria guidelines member
Associate Professor Kristen Scarpato, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: SUO Education Committee, AUA Core Curriculum,
Urology Practice Editorial Committee
Professor Yair Lotan, MD
Institution: UT Southwestern Medical Center
Relationship: Consultant, CAB member, IIT PI, CT PI
Brief Bio: Published >500 articles. Contributor to AUA/ASCO/ASTRO
MIBC and hematuria guidelines. Chair of AUA Core Curriculum. BCAN
Adboard
Professor Sam Chang, MD, MBA
Institution: Vanderbilt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >200 articles. Chair of AUA NMIBC Guidelines,
SUO Executive Board, ABU/AUA Examination Committee, BCAN
Adboard, AUA representative to the AJCC
Assistant Professor John Sfakianos
Institution: Icahn School of Medicine at Mount Sinai
Relationship: Consultant, CAB member
Brief Bio: Published >20 articles. Reviewer for J Urol and Urologic
Oncology
Professor Dan Barocas, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. AUA guidelines panel for
microscopic hematuria. Reviewer for AUA educational materials
Associate Professor, Siamak Daneshmand, MD
Institution: Keck School of Medicine at USC
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >200 articles. Editorial board of the J Urol,
Bladder Cancer Journal, Current Opinions in Urology, BCAN Adboard,
AUA/SUO Guideline Committee on NMIBC
ASCO: American Society of Clinical Oncology
ASTRO: American Society of Radiation Oncology
AUA: American Urological Association
BCAN: Bladder Cancer Advocacy Network
CAB: Clinical Advisory Board
CT PI: Clinical Trials Principal Investigator
FACS: Fellow of the American College of Surgeons
IIT PI: Investigator Initiated Trial Principal Investigator
J Urol: Journal of Urology
KOL: Key Opinion Leader
MPH: Master of Public Health
SUO: Society of Urologic Oncology
37

2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
2014
Dec 2014
Launch of
Cxbladder
Triage
2015
Dec 2015
Launch of
Cxbladder
Monitor
2016
2018
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2019
2020
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
Medicare
reimbursement of
Cxbladderat
$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
Oct 2021
PEB raises
$103.5m
(~US$72.5m)
2022
Dec 2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
38
2023
Nov 2023
Kaiser
Permanente
EMR
integration
goes live
2024
May 2024
STRATA podium
presentation at
AUA 2024.
Study published
in Journal of
Urology
PACIFIC EDGE – TAKING NEW ZEALAND INNOVATION GLOBAL

INDEPENDENT DIRECTORS
SARAH PARK
ANATOLE MASFEN
BRYAN WILLIAMS
ANNA STOVE
TONY BARCLAY
CHRIS GALLAHER
Chairman
Chris has held senior positions in
both CEO and CFO roles with large
international companies and was a
partner in Arthur Young, Chartered
Accountants. Prior to retiring from
full time corporate life, he was CFO
of Fulton Hogan, a large New
Zealand civil contractor
DR PETER MEINTJES
Chief Executive Officer
Peter is a molecular diagnostics and
genomics leader focused on
nascent market development of
disruptive innovations to drive
commercial success. Prior to joining
Pacific Edge, he was based in
Boston in a succession of diagnostic
leadership roles. Most recently he
was the Chief Commercial Officer
at Eurofins Transplant Genomics
and before that he was CEO at
Omixon
SENIOR LEADERSHIP TEAM
GRANT GIBSON DAVID LEVISON DR TAMER ABOUSHWAREB
Chief Financial Officer President Pacific Edge Diagnostics USA Chief Medical Officer
GLEN COSTIN DARELL MORGAN DR JUSTIN HARVEY
President Asia Pacific Chief Operating Officer Chief Technology Officer
ANDY MCINTOSH PROFESSOR PARRY GUILFORD
Chief Digital Officer Chief Scientific Officer
PACIFIC EDGE BOARD AND MANAGEMENT
39

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 563
email: investors@pacificedge.co.nz
www.pacificedgedx.com
40

---

FOR THE SIX MONTHS ENDED
30 SEPTEMBER 2024
CONSOLIDATED
INTERIM FINANCIAL
STATEMENTS

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
NOTES
UNAUDITED
SEPT 2024
6 MONTHS
($000)
UNAUDITED
SEPT 2023
6 MONTHS
($000)
AUDITED
MARCH 2024
12 MONTHS
($000)
REVENUE
Operating Revenue 4 10,959 13,095 23,907
Total Operating Revenue 10,959 13,095 23,907
Other Income4 385 859 1,322
Interest Income 1,193 1,892 3,433
Foreign Exchange Gain / (Loss) (382) 734 631
Total Revenue and Other Income 12,155 16,580 29,293
OPERATING EXPENSES
Laboratory Operations 5,958 6,141 11,751
Research 7,230 5,487 12,089
Sales and Marketing 8,245 14,339 25,590
General and Administration 5,225 5,865 9,398
Total Operating Expenses5 26,658 31,832 58,828
NET LOSS BEFORE TAX (14,503) (15,252) (29,535)
Income Tax Expense - - -
LOSS FOR THE YEAR AFTER TAX (14,503) (15,252) (29,535)
Items that may be reclassified to profit or loss:
Translation of Foreign Operations (155) 198 142
Disposal of Foreign Operation - - (20)
TOTAL COMPREHENSIVE LOSS atttributable
to equity holders of the Company
(14,658) (15,054) (29,413)
Earnings per share for loss attributable to the
equity holders of the Company during the year
Basic and Diluted Earnings per share (0.018) (0.019) (0.036)
Consolidated Interim Financial Statements
Consolidated Statement of Comprehensive Income 3
Consolidated Statement of Changes in Equity 4
Consolidated Balance Sheet 6
Consolidated Statement of Cash Flows 7
Notes to the Financial Statements
1. Summary of Accounting Policies 8
2. Investment and Advances in Subsidiaries 10
3. Dividends 10
4. Revenue and Other Income 10
5. Operating Expenses 11
6. Segment Information 12
7. Share Capital 16
8. Reconciliation of Cash Flows to Operating
Activities with Operating Net Loss 17
9. Contingent Liabilities 17
10. Capital Commitments 17
11. Subsequent Events 17
12. Related Parties 18
13. Proposed Local Coverage Determination (LCD)
Changes – Potential Impact on Revenue 18
14. Net Tangible Assets 19
3 2

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
NOTES
SHARE
CAPITAL
ACCUMULATED
LOSSES
SHARE BASED
PAYMENTS
RESERVE
FOREIGN CURRENCY
TRANSLATION
RESERVE
TOTAL
EQUITY
($000)($000)($000)($000)($000)
UNAUDITED 6 MONTHS TO 30 SEPT 2023
Balance as at 31 March 2023 294,317 (216,814) 4,418 842 82,763
Loss After Tax - (15,252) - - (15,252)
Other Comprehensive Income - (8) - 206 198
Total Comprehensive Loss atttributable to equity holders of the Company - (15,260) - 206 (15,054)
Transactions with owners in their capacity as owners:
Share Based Payments - Employee Remuneration7 38 - - - 38
Share Based Payment - Employee Share Options7 - - 555 - 555
Balance as at 30 September 2023 294,355 (232,074) 4,973 1,048 68,302
UNAUDITED 6 MONTHS TO 30 SEPT 2024
Balance as at 31 March 2024 294,400 (246,349) 5,607 964 54,622
Loss After Tax - (14,503) - - (14,503)
Other Comprehensive Income - - - (155) (155)
Total Comprehensive Loss atttributable to equity holders of the Company - (14,503) - (155) (14,658)
Transactions with owners in their capacity as owners:
Share Based Payments - Employee Remuneration7 58 - - - 58
Share Based Payment - Employee Share Options7 - 63 571 - 634
Balance as at 30 September 2024 294,458 (260,789) 6,178 809 40,656
AUDITED 12 MONTHS TO 31 MARCH 2024
Balance as at 31 March 2023 294,317 (216,814) 4,418 842 82,763
Loss After Tax - (29,535) - - (29,535)
Other Comprehensive Income - - - 122 122
Total Comprehensive Loss atttributable to equity holders of the Company - (29,535) - 122 (29,413)
Transactions with owners in their capacity as owners:
Share Based Payments - Employee Remuneration7 83 - - - 83
Share Based Payment - Employee Share Options7 - - 1,189 - 1,189
Balance as at 31 March 2024 294,400 (246,349) 5,607 964 54,622
5 4

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.
For and on behalf of the Board of Directors:
Director Director
Dated 25th day of November 2024
AS AT 30 SEPTEMBER 2024
CONSOLIDATED BALANCE SHEET
NOTES
UNAUDITED
SEPT 2024
6 MONTHS
UNAUDITED
SEPT 2023
6 MONTHS
AUDITED
MARCH 2024
12 MONTHS
($000)($000)($000)
CURRENT ASSETS
Cash and Cash Equivalents 21,931 20,469 29,261
Short Term Deposits 14,000 41,705 21,000
Receivables 5,143 5,239 4,698
Inventory 1,335 1,676 1,688
Other Assets 1,905 1,688 1,228
Total Current Assets 44,314 70,777 57,875
NON-CURRENT ASSETS
Property, Plant and Equipment 2,728 2,945 2,925
Right of Use Assets 2,902 1,376 3,698
Intangible Assets 907 1,156 950
Total Non-Current Assets 6,537 5,477 7,573
TOTAL ASSETS 50,851 76,254 65,448
CURRENT LIABILITIES
Payables and Accruals 6,869 6,539 6,753
Borrowings 300 - 300
Lease Liabilities 1,260 529 1,264
Total Current Liabilities 8,429 7,068 8,317
NON-CURRENT LIABILITIES
Lease Liabilities 1,766 884 2,509
Total Non-Current Liabilities 1,766 884 2,509
TOTAL LIABILITIES 10,195 7,952 10,826
NET ASSETS 40,656 68,302 54,622
Represented by:
EQUITY
Share Capital7 294,458 294,355 294,400
Accumulated Losses (260,789) (232,074) (246,349)
Share Based Payments Reserve 6,178 4,973 5,607
Foreign Translation Reserve 809 1,048 964
TOTAL EQUITY 40,656 68,302 54,622
FURTHER INFORMATION:
Net Tangible Assets Per Share ($)14 0.049 0.083 0.066
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
CONSOLIDATED STATEMENT OF CASH FLOWS
NOTES
UNAUDITED
SEPT 2024
6 MONTHS
UNAUDITED
SEPT 2023
6 MONTHS
AUDITED
MARCH 2024
12 MONTHS
($000)($000)($000)
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers 11,125 13,576 24,137
Receipts from Research Tax Incentives and
Grant Providers
16 1,371 1,856
Interest Received 995 1,228 3,441
12,136 16,175 29,434
Cash was disbursed to:
Payments to Suppliers and Employees 24,567 31,080 55,196
Net GST outflow (inflow) 43 87 (12)
24,610 31,167 55,184
Net Cash Flows To Operating Activities8 (12,474) (14,992) (25,750)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash was provided from:
Proceeds from Short Term Deposits 34,000 35,703 83,084
34,000 35,703 83,084
Cash was disbursed to:
Purchase of Short Term Deposits 27,145 32,846 59,523
Capital Expenditure on Plant and Equipment 278 487 832
Capital Expenditure on Intangible Assets 252 302 540
27,675 33,635 60,895
Net Cash Flows From Investing Activities 6,325 2,068 22,189
CASH FLOWS TO FINANCING ACTIVITIES:
Cash was received from:
Proceeds from Borrowings - - 300
- -300
Cash was disbursed to:
Repayment of Leases - Principal 614 675 1,268
Repayment of Leases - Interest 118 32 138
732 707 1,406
Net Cash Flows To Financing Activities (732) (707) (1,106)
Net Decrease in Cash Held (6,881) (13,631) (4,667)
Add Opening Cash Brought Forward 29,261 33,229 33,229
Effect of Exchange Rate Changes on Net Cash (449)871 699
Ending Cash Carried Forward 21,931 20,469 29,261
7 6

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
1 . SUMMARY OF ACCOUNTING POLICIES
The unaudited consolidated interim financial statements (“Interim Financial Statements”)
presented are those of Pacific Edge Limited (“Company”) and its subsidiaries (“Group”).
The Company is registered and domiciled in New Zealand. The Group’s purpose is to
research, develop and commercialise diagnostic and prognostic tools for the early
detection and management of cancers. Pacific Edge Diagnostics New Zealand Limited and
Pacific Edge Diagnostics USA Limited manage and operate the laboratories used for the
detection of bladder cancer. Pacific Edge (Australia) Pty Limited’s purpose is to research
and develop the Cxbladder products and other prognostic tools. Pacific Edge Diagnostics
Singapore Pte Limited’s purpose is sales and marketing of bladder cancer products and
assisting with research and development. Pacific Edge Analytical Services Limited is a
dormant entity.
The Company is a for profit entity, registered in New Zealand under the Companies Act
1993 and is a reporting entity for the purposes of the Financial Markets Conduct Act
2013. The Company is dual listed, with its primary listing of ordinary shares quoted in New
Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt
Entity on the ASX.
a) Basis of Preparation of Financial Statements
The Interim Financial Statements for the six months ended 30 September 2024 have
been prepared in accordance with New Zealand Generally Accepted Accounting Practice
(GAAP) and the Financial Markets Conduct Act 2013. They comply with the New Zealand
Equivalents to International Financial Reporting Standards (NZ IFRS) and other guidance as
issued by the External Reporting Board, as appropriate for entities, and with International
Financial Reporting Standards.
The Interim Financial Statements have been prepared in accordance with NZ IAS 34 -
Interim Financial Reporting. In complying with NZ IAS 34, these consolidated Interim
Financial Statements also comply with IAS 34 - Interim Financial Reporting and should be
read in conjunction with the Company’s 2024 Annual Report.
The Interim Financial Statements are prepared on the basis of historical cost, except where
otherwise identified. The presentational currency used in the preparation of the financial
statements is New Zealand dollars and all values are rounded to the nearest thousand
dollars ($000).
b) Accounting Policies and Accounting Estimates
All material accounting policies have been applied on a basis consistent with those used in
the audited financial statements of Pacific Edge Limited for the year ended 31 March 2024.
c) Authorisation
The Interim Financial Statements were authorised by the Board of Directors on
25 November 2024. The Annual Financial Statements for the year ended 31 March 2024
were authorised by the Board of Directors on 20 May 2024.
d) Audit
The Interim Financial Statements for the six months ended 30 September 2024 are
unaudited. Comparative balances for 30 September 2023 are unaudited, whilst the
comparative balances for 31 March 2024 are audited.
e) Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Interim
Financial Statements are as follows:
Ownership Interests
& Voting Rights
Name of Subsidiary
Place of
Incorporation
(or registration)
and Operation
Principal Activity
30 Sept
2024
(%)
30 Sept
2023
(%)
Pacific Edge Diagnostics
New Zealand Limited
New Zealand
Commercial Sales and
Diagnostic Laboratory
100100
Pacific Edge (Australia)
Pty Limited
Australia
Commercial Sales and
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics
USA Limited
USA
Commercial Sales and
Diagnostic Laboratory
100100
Pacific Edge Singapore
Pte Limited
Singapore
Dormant - In the process
of being dissolved as
at 30 September 2024
(FY24: Commercial
Sales)
100100
Pacific Edge Analytical
Services Limited
New ZealandDormant Company100100
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
9 8

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
2. INVESTMENT AND ADVANCES IN SUBSIDIARIES
The consolidated Interim Financial Statements incorporate the assets and liabilities and
results of Pacific Edge Diagnostics New Zealand Limited, Pacific Edge (Australia) Pty
Limited, Pacific Edge Diagnostics USA Limited, Pacific Edge Diagnostics Singapore Pte
Limited and Pacific Edge Analytical Services Limited, all of which are 100% owned by the
Company. Subsidiaries have a 31 March balance date. The investments in and advances to
subsidiaries are eliminated on consolidation in the Group financial statements.
3. DIVIDENDS
The Company does not propose to pay dividends to shareholders similar to previous years.
This policy continues.
4. REVENUE AND OTHER INCOME
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Cxbladder SalesCxbladder Sales
- US - Accrual Accounting- US - Accrual Accounting 8,889 8,889 11,40311,403 19,288 19,288
- US - Cash Accounting- US - Cash Accounting 1,178 1,178 1,0621,062 3,214 3,214
- Total US Sales- Total US Sales 10,067 10,067 12,46512,465 22,502 22,502
- Rest of World- Rest of World 892 892 630630 1,405 1,405
Total Operating Revenue Total Operating Revenue 10,959 10,959 13,09513,095 23,907 23,907
Other IncomeOther Income
Grant IncomeGrant Income--33 24 24
Research Rebates and Tax IncentivesResearch Rebates and Tax Incentives 385 385 856856 1,298 1,298
Total Other IncomeTotal Other Income 385 385 859859 1,322 1,322
5. OPERATING EXPENSES
The note below highlights total expenses shown within total operating expenses. These
items are then split across functions laboratory, research, sales and marketing and general
and administration as reported in the annual report.

Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Operating ExpensesOperating Expenses
AmortisationAmortisation 295 295 178178 621 621
Auditors Remuneration Auditors Remuneration
- Group year end financial statements- Group year end financial statements 99 99 9797 194 194
- Half year review of financial statements- Half year review of financial statements 35 34 34
- Foreign statutory financial statements - 25 -
Other services provided by PricewaterhouseCoopers Other services provided by PricewaterhouseCoopers
New ZealandNew Zealand
1 1 2 2
Total Auditors RemunerationTotal Auditors Remuneration 135 156 230
Consultant CostsConsultant Costs 1,149 1,366 2,432
DepreciationDepreciation 390 370 716
Depreciation on Right of Use AssetsDepreciation on Right of Use Assets 661 661 635635 1,267 1,267
Directors FeesDirectors Fees 247 247 500
Employee BenefitsEmployee Benefits 12,784 12,784 15,70015,700 29,097 29,097
Employee Share Scheme ExpensesEmployee Share Scheme Expenses 58 58 3838 83 83
Employee Share OptionsEmployee Share Options 635 635 555555 1,189 1,189
Interest on Lease LiabilitiesInterest on Lease Liabilities 118 118 3232 138 138
Legal ExpensesLegal Expenses 256 256 620620 826 826
NZX / ASX / Registry FeesNZX / ASX / Registry Fees 124 124 146146 274 274
Rental and Lease ExpenseRental and Lease Expense 75 68 151
Site Fees - Clinical StudiesSite Fees - Clinical Studies 2,062 1,358 3,154
Other Operating ExpensesOther Operating Expenses 7,669 7,669 10,36310,363 18,150 18,150
Total Operating ExpensesTotal Operating Expenses 26,658 26,658 31,83231,832 58,828 58,828
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
11 10

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Employee Share Scheme
Employee Share Scheme Expenses are a non-cash expense. These relate to shares issued
to employees in lieu of cash bonuses.
Employee Share Options
Employee Share Options are a non-cash expense. Refer to Note 8 of the Annual Report for
details of the accounting policy for Employee Share Schemes.
Other Operating Expenses
The major categories of expenditure which make up operating expenses, but are not
disclosed separately above: Laboratory costs, Information Technology costs, Compliance
and Regulatory costs, Investor Relations costs.
6. SEGMENT INFORMATION
Operating segments are reported in a manner consistent with the internal reporting
provided to the chief operating decision-maker. The chief operating decision-maker,
who is responsible for allocating resources and assessing performance of the operating
segments, has been identified as the Chief Executive Officer who makes strategic
decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the
commercial businesses worldwide; and
2. Research: The research and development of diagnostic and prognostic products for
human cancer.
The reportable operating segment Commercial derives its revenue primarily from sales
of Cxbladder tests and the reportable operating segment Research derives its revenue
primarily from grant income. The Chief Executive Officer assesses the performance of the
operating segments based on net loss for the period.
Segment income, expenses and profitability are presented on a gross basis excluding
inter-segment eliminations to best represent the performance of each segment operating
as independent business units. The segment information provided to the Chief Executive
Officer for the reportable segments described above, for the six months ended
30 September 2024 is shown on the following page.
Unaudited 6 Months
to 30 September 2024
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External10,959 - - 10,959
Other Income 617785 (1,017)385
Interest Income71,186 - 1,193
Foreign Exchange Gain- (382) - (382)
Total Income11,5831,589 (1,017)12,155
Expenses
Expenses15,81410,516 (1,017)25,313
Depreciation & Amortisation 890 455 - 1,345
Total Operating Expenses16,70410,971 (1,017)26,658
Loss Before Tax (5,121) (9,382) - (14,503)
Income Tax Expense - - - -
Loss After Tax (5,121) (9,382) - (14,503)
Net Cash Flow to Operating Activities (4,109) (8,365) - (12,474)
Unaudited 6 Months
to 30 September 2023
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External13,095 - - 13,095
Other Income 2761,403 (820)859
Interest Income141,878 - 1,892
Foreign Exchange Gain - 734 - 734
Total Income13,3854,015 (820)16,580
Expenses
Expenses21,7919,678 (820)30,649
Depreciation & Amortisation 801 382 - 1,183
Total Operating Expenses22,59210,060 (820)31,832
Loss Before Tax (9,207) (6,045) - (15,252)
Income Tax Expense - - - -
Loss After Tax (9,207) (6,045) - (15,252)
Net Cash Flow to Operating Activities (9,114) (5,878) - (14,992)
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
13 12

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Audited 12 Months
to 31 March 2024
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External 23,871 - 36 23,907
Other Income 489 4,400 (3,567) 1,322
Interest Income 21 3,412 - 3,433
Foreign Exchange Gain 1 666 (36) 631
Total Income 24,382 8,478 (3,567) 29,293
Expenses
Expenses 40,008 19,781 (3,567) 56,222
Depreciation & Amortisation 1,629 977 - 2,606
Total Operating Expenses 41,637 20,758 (3,567) 58,828
Loss Before Tax (17,255) (12,280) - (29,535)
Income Tax Expense - - - -
Loss After Tax (17,255) (12,280) - (29,535)
Net Cash Flow to Operating Activities (14,447) (11,303) - (25,750)
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent. These
are eliminated on consolidation of Group results. The Research segment of the business
utilise consumables and other components that are purchased by the Commercial
segments of the business, with the costs of these components allocated to Research
segment, and the Commercial segment recognising revenue from the sale.
Total Laboratory Throughput:
Unaudited
Commercial
# Tests
Research
# Tests
Total
# Tests
6 months ended 30 September 202412,3231,91014,233
6 months ended 30 September 2023 15,401 2,83918,240
12 months ended 31 March 2024 27,347 5,286 32,633
Laboratory Throughput is a key metric for the Group. Laboratory Throughput provides
evidence of the usage of Cxbladder products globally and the rates of adoption between
different customer segments. Total Laboratory Throughput includes commercial tests,
which are invoiced to customers, and research tests which are not considered to be
billable as these tests relate to user programs or other non-chargeable activities.
Commercial test numbers are also a key metric for the Group: Commercial Tests are those
tests for which the Company is actively seeking reimbursement and cash receipts, and
tests performed at no charge in order to gain new customers.
Segment Assets and Liabilities Information:
Unaudited as at 30 September 2024
Commercial
($000)
Research
($000)
Total
($000)
Total Assets10,359 40,492 50,851
Total Liabilities 6,106 4,089 10,195
Unaudited as at 30 September 2023
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 8,152 68,102 76,254
Total Liabilities 4,585 3,367 7,952

Audited as at 31 March 2024
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 11,443 54,005 65,448
Total Liabilities 6,871 3,955 10,826
Additions to non current assets for the six months ended 30 September 2024 include:
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant & Equipment 274 4 278
Intangible Assets 252 - 252
Total Additions to Non Current Assets 526 4 530
The amounts provided to the Chief Executive Officer with respect to total assets and total
liabilities are measured in a manner consistent with that of the financial statements. These
assets and liabilities are allocated based on the operation of the segment and the physical
location of the asset.
There are no unallocated assets or liabilities.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
15 14

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
Segment Assets and Liabilities Information
The Group generates most of the operating revenue from Commercial tests from the
US and New Zealand and also receives Grant revenue from New Zealand. Rest of World
consists of Revenue from Australia and Southeast Asia.
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Operating and Grant Revenue
US10,067 12,465 22,502
New Zealand 1,228 1,436 2,641
Rest of World 49 53 86
Total Operating and Grant Revenue 11,344 13,954 25,229
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Non-Current Assets
US 3,469 1,736 4,343
New Zealand 3,066 3,740 3,229
Rest of World 2 1 1
Total Non-Current Assets 6,537 5,477 7,573
7. SHARE CAPITAL
6 Months
Shares
(000)
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Opening Balance 811,271 294,400 294,317 294,317
Issue of Ordinary Shares
- Employee Remuneration
1
645 58 38 83
Movement 645 58 38 83
Closing Balance 811,916 294,458 294,355 294,400
1
During the period 644,630 shares were issued as part of employees remuneration in lieu of cash payments at an
average price of $0.090 per share. (September 2023: 351,894 at $0.107 and March 2024: 906,126 at $0.091).
There are 811,915,974 (September 2023: 810,717,112 and March 2024: 811,271,344) ordinary
shares on issue. All fully paid shares in the Company have equal voting rights and equal
rights to dividends. All Ordinary Shares are fully paid and have no par value.
8. RECONCILIATION OF CASH FLOWS TO OPERATING ACTIVITIES WITH
OPERATING NET LOSS
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Net Loss for the PeriodNet Loss for the Period (14,503) (14,503) (15,252) (15,252) (29,535) (29,535)
Add Non Cash Items:Add Non Cash Items:
DepreciationDepreciation 390 390 370 370 716 716
Loss on disposal of Property, Plant and EquipmentLoss on disposal of Property, Plant and Equipment - - 2 2 14 14
AmortisationAmortisation 295 295 178 178 621 621
Employee Share options 635 555 1,189
Employee bonuses paid in shares in lieu of cash 58 38 83
Depreciation on right of use assets 661 635 1,267
Interest on finance leases shown in lease
repayments
118 32 138
Total Non Cash Items 2,157 1,810 4,028
Add Movements in Other Working Capital items: (978) (37) 964
(Increase) Decrease in Receivables and Other Assets 353 (389) (401)
(Increase) Decrease in Inventory 116 (390) (174)
Increase (Decrease) in Payables and Accruals 381 (734) (632)
Total Movement in Other Working CapitalTotal Movement in Other Working Capital (128) (128) (1,550) (1,550) (243) (243)
Net Cash Flows to Operating ActivitiesNet Cash Flows to Operating Activities (12,474) (12,474) (14,992) (14,992) (25,750) (25,750)
9. CONTINGENT LIABILITIES
There were no known contingent liabilities at 30 September 2024 (September 2023: Nil
and March 2024: Nil). The Company and Group have not granted any securities in respect
of liabilities payable by any other party whatsoever.
10. CAPITAL COMMITMENTS
There are no capital commitments at 30 September 2024 (September 2023: Nil and March
2024: Nil).
11. SUBSEQUENT EVENTS
There are no subsequent events.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTS
17 16

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2024
12.RELATED PARTIES
Details of all related party relationships have been disclosed in the annual report for the
year ended 31 March 2024. No new transactions with directors occurred that would be
considered a related party.
13.PROPOSED LOCAL COVERAGE DETERMINATION (LCD) CHANGES -
POTENTIAL IMPACT ON REVENUE
On 3 July 2020* Pacific Edge received notice of inclusion in the LCD resulting in the
Company receiving reimbursement for Cxbladder Monitor and Detect tests from that date.
On 29 July 2022*, Pacific Edge became aware of proposed changes to the LCD/LCA
whereby if the proposed changes were issued as published then Cxbladder would no
longer have coverage and the Company would not qualify for reimbursement.
On 2 June 2023* Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction
for Pacific Edge’s US laboratory issued a final Local Coverage Determination (LCD) L39365
that governs the reimbursement of Cxbladder in the US by the US Centres for Medicare
& Medicaid Services (CMS). The LCD determined that Cxbladder would not qualify for
coverage from Novitas for tests reimbursed by the CMS from 17 July 2023. These tests
represent a significant portion of Cxbladder testing revenue. Multiple companies that had
existing coverage or are seeking coverage, were similarly impacted by this proposal.
On 6 July 2023* Pacific Edge received notification that LCD L39365 would not become
final and Novitas would propose it again as a draft LCD DL39365. The new draft would
be subject to ‘notice and comment’ for 45 days including an open public meeting and a
written comment submission period. 
On 27 July 2023* Pacific Edge became aware that Novitas had republished the LCD
(DL39365) without any changes from LCD L39365, which if approved without further
changes would mean Cxbladder (and multiple other products from various companies)
would not qualify for coverage from Novitas for tests reimbursed by the CMS.
Novitas provided for the statutory requirement for a 45-day notice and comment period
commencing 27 July 2023* and finishing 9 September 2023*, during which time all
interested stakeholders were able to submit comments to Novitas. Pacific Edge, and a
number of impacted parties submitted written submissions that argue Cxbladder Triage,
Detect and Monitor tests should retain Medicare coverage based on the clinical value they
offer to patients, clinicians, and healthcare payers.
Novitas was expected to withdraw or finalize the LCD within 365 days from the original
publication date (27 July 2023*) and include a response to those comments. On 26 July
2024* Novitas confirmed it had been granted an extension to finalize or withdraw the
LCD. At the time of signing these interim financial statements, the Board does not have a
revised date that Novitas will finalize or withdraw the LCD.
If finalized, Novitas must provide a minimum of 45 days’ notice before the LCD becomes
effective.
Pacific Edge received payment in line with the existing LCD/LCA (Local Coverage Article)
for the six months ended 30 September 2024, and to the date of approval of these
consolidated interim financial statements.
In the six months to 30 September 2024, tests processed through our laboratory for
Medicare and Medicare Advantage patients represented approximately 54% of US
commercial test volumes and generated approximately NZ $6.5m, or 59% of Pacific Edge’s
total operating revenue.
During the six months to 30 September 2024, Pacific Edge continued to progress
initiatives that will assist in mitigating reimbursement risk, including the development
of further clinical evidence validating the performance of Cxbladder and providing the
catalyst for language supportive of Cxbladder in the American Urological Association
microhematuria guideline currently under review. In addition, the company has continued
to progress commercialization of Triage Plus which has demonstrated improved
performance characteristics and has the expectation of delivering an improved margin.
Whilst the LCD has yet to be finalised and the full impact on the Group is unable to be
determined, management and the Board have modelled a number scenarios relating
to possible LCD outcomes. Under all modelled scenarios there is sufficient liquidity
in the form of cash and short term deposits to meet obligations and continue for the
foreseeable future, being at least 12 months from the date of approval of the consolidated
interim financial statements. Accordingly, it is the Board’s view that there are no material
uncertainties related to events or conditions that may cast significant doubt upon
the entity’s ability to continue as a going concern for the purpose of these financial
statements.
*All dates with an asterisk refer to US dates
14.NET TANGIBLE ASSETS
Net Tangible Assets per share is a non-GAAP measure that is required to be disclosed by
the NZX Listing Rules. The calculation of the Group’s Net Tangible Assets per share and its
reconciliation to the consolidated balance sheet is presented below.
Unaudited
Sept 2024
6 Months
($000)
Unaudited
Sept 2023
6 Months
($000)
Audited
March 2024
12 Months
($000)
Total AssetsTotal Assets 50,851 50,851 76,25476,25465,44865,448
Less Intangible AssetsLess Intangible Assets 907 907 1,1561,156950950
Less Total LiabilitiesLess Total Liabilities 10,195 10,195 7,9527,952 10,826 10,826
Net Tangible Assets 39,749 67,146 53,672
Number of Shares Issued (000’s) 811,916 810,717 811,271
Net Tangible Assets Per ShareNet Tangible Assets Per Share $0.049 $0.049 $0.083 $0.083 $0.066 $0.066
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
NOTES TO THE FINANCIAL STATEMENTSNOTES TO THE FINANCIAL STATEMENTS
19 18

Independent auditor’s review report
To the shareholders of Pacific Edge Limited
Report on the consolidated interim financial statements
Our conclusion
We have reviewed the consolidated interim financial statements of Pacific Edge Limited (the
Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at
30 September 2024, and the consolidated statement of comprehensive income, the consolidated
statement of changes in equity and the consolidated statement of cash flows for the six months ended
on that date, and notes, comprising material accounting policy information and other explanatory
information .
Based on our review, nothing has come to our attention that causes us to believe that the
accompanying consolidated interim financial statements of the Group do not present fairly, in all
material respects, the financial position of the Group as at 30 September 2024, and its financial
performance and cash flows for the six months then ended, in accordance with International
Accounting Standard 34 Interim Financial Reporting (IAS 34) and New Zealand Equivalent to
International Accounting Standard 34 Interim Financial Reporting (NZ IAS 34).
Basis for conclusion
We conducted our review in accordance with the New Zealand Standard on Review Engagements
2410 (Revised) Review of Financial Statements Performed by the Independent Auditor of the Entity
(NZ SRE 2410 (Revised)). Our responsibilities are further described in the Auditor’s responsibilities for
the review of the consolidated interim financial statements section of our report.
We are independent of the Group in accordance with the relevant ethical requirements in
New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other
ethical responsibilities in accordance with these ethical requirements. In addition to our role as auditor,
our firm carries out other services for the Group including training workshop. The provision of this
other service has not impaired our independence.
Responsibilities of Directors for the consolidated interim financial statements
The Directors of the Company are responsible on behalf of the Company for the preparation and fair
presentation of these consolidated interim financial statements in accordance with IAS 34 and
NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the
preparation and fair presentation of the consolidated interim financial statements that are free from
material misstatement, whether due to fraud or error.
Auditor’s responsibilities for the review of the consolidated interim financial statements
Our responsibility is to express a conclusion on the consolidated interim financial statements based on
our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our
attention that causes us to believe that the consolidated interim financial statements, taken as a
whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34.
A review of consolidated interim financial statements in accordance with NZ SRE 2410 (Revised) is a
limited assurance engagement. We perform procedures, primarily consisting of making enquiries,
primarily of persons responsible for financial and accounting matters, and applying analytical and other
review procedures. The procedures performed in a review are substantially less than those performed
in an audit conducted in accordance with International Standards on Auditing and International
Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that
we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated
interim financial statements.
PricewaterhouseCoopers, PwC Centre, 60 Cashel Street, PO Box 13-244, Christchurch 8141, New Zealand
T: +64 3 374 3000, www.pwc.co.nz

Who we report to
This report is made solely to the Company’s Shareholders, as a body. Our review work has been
undertaken so that we might state those matters which we are required to state to them in our review
report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Shareholders, as a body, for our review procedures, for this
report, or for the conclusion we have formed.
The engagement partner on the review resulting in this independent auditor’s review report is Maxwell
John Dixon.
For and on behalf of:
PricewaterhouseCoopers Christchurch
25 November 2024
PwC

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 (overseas) | 0800 555 563 (NZ)

F +64 3 974 9393
www.pacificedgedx.com

---

Template
Results announcement
(for Equity Security issuer/Equity and Debt Security issuer)
Updated as at June 2023

Please do not amend or delete individual rows. As this template relates to prescribed content, changes to content
should only be made where it is clearly indicated that this is permitted, otherwise, if an Issuer considers a particular
element does not apply, mark the row as N/A, Any other changes to this prescribed form must first be approved by
NZX as required under NZX Listing Rule 3.26.1.

Results for announcement to the market
Name of issuer Pacific Edge Limited
Reporting Period 6 months to 30 September 2024
Previous Reporting Period 6 months to 30 September 2023
Currency NZD (New Zealand Dollar)
Amount (000s) Percentage change
Revenue from continuing
operations
$10,959 16% Decrease
Total Revenue $12,155 27% Decrease
Net profit/(loss) from
continuing operations
($14,503) 5% Smaller Loss
Total net profit/(loss) ($14,503) 5% Smaller Loss
Interim/Final Dividend
Amount per Quoted Equity
Security
The Company does not propose to pay dividends to
shareholders
Imputed amount per Quoted
Equity Security
Not Applicable
Record Date Not Applicable
Dividend Payment Date Not Applicable
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.049 $0.083
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
For commentary on the results, please refer to the commentary
in the accompanying NZX release. Further information is also
set out in the unaudited financial statements of the Company for
the 6 months to 30 September 2024 which accompany this
Results Announcement.
Authority for this announcement
Name of person

authorised
to make this announcement
Grant Gibson
Contact person for this
announcement
Grant Gibson
Contact phone number 0800 555 563
Contact email address grant.gibson@pelnz.com
Date of release through MAP

26/11/2024

Unaudited financial statements accompany this announcement.